Aditx Therapeutics, Inc.: insider trades · United States · SEC (Form 4)

About Aditx Therapeutics, Inc.

Aditxt, Inc. (NASDAQ: ADTX) is a U.S.-based health and biotechnology company listed in the United States on the NASDAQ market. The company is headquartered in Mountain View, California, and was incorporated in 2017. Its common stock began trading on the Nasdaq Capital Market in June 2020. Aditxt is not a single-product biopharma story; instead, it presents itself as a platform company focused on identifying, securing, developing, and commercializing promising health innovations. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1726711/000121390025026256/ea0235549-10k_aditxt.htm?utm_source=openai)) The company’s business model is centered on building innovation assets into standalone programs or subsidiaries. Aditxt’s original internal focus was ADI/Adimune, an immune-modulation technology initially aimed at improving outcomes for organ-transplant patients. Over time, the company broadened its scope to include additional health innovation initiatives, including programs tied to immune-system monitoring and modulation, diagnostics, and other precision-medicine opportunities. In SEC filings, Aditxt describes a process of securing innovations, surrounding them with operational and commercialization support, and helping them mature into monetizable businesses. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1726711/000121390025026256/ea0235549-10k_aditxt.htm?utm_source=openai)) From a competitive standpoint, Aditxt operates in a highly fragmented, capital-intensive segment where valuation is driven less by current revenue scale and more by scientific execution, intellectual property, regulatory milestones, and partnership activity. The company is not a large integrated pharmaceutical group. Rather, it behaves like a development-stage innovation platform with high upside optionality and correspondingly high risk. That profile can attract investors looking for asymmetric exposure to early-stage healthcare assets, but it also implies meaningful dilution risk and a recurring need for external financing, which is reflected in recent SEC disclosures. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1726711/000121390024099697/ea0220737-10q_aditxt.htm?utm_source=openai)) Recent developments suggest that Aditxt continues to pursue portfolio expansion and transaction-driven growth, including efforts involving health-related assets and corporate structuring. At the same time, the company’s filings indicate that it remains in a development phase and requires additional capital to fund operations and clinical work. For investors in the French-speaking markets, ADTX should therefore be viewed as a speculative U.S. micro-cap biotechnology name on NASDAQ, highly sensitive to clinical updates, regulatory progress, licensing deals, capital raises, and any material insider-transaction signals filed on SEC Form 4. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1726711/000121390024030466/ea020332801ex99-1_aditxtinc.htm?utm_source=openai))